Home Events Molecular Biomarkers with Predictive Value in Metastatic Lung Cancer, Metastatic Colorectal Cancer and Unresectable and Metastatic Melanoma

Molecular Biomarkers with Predictive Value in Metastatic Lung Cancer, Metastatic Colorectal Cancer and Unresectable and Metastatic Melanoma

Date

February 17 2021

Time

1:00 pm - 2:30 pm

Speakers

  • Dr. Brandon Sheffield
    Dr. Brandon Sheffield

    Dr. Sheffield is an anatomic and molecular pathologist. He is currently serving as the Medical Director of Immunohistochemistry and Molecular Pathology and the Physician Lead of Research for the William Osler Health System in Canada. Dr. Sheffield focuses on the delivery of personalized medicine and precision oncology and making molecular testing available to community cancer patients in Canada.

  • Dr. Parneet Cheema
    Dr. Parneet Cheema

    Dr. Cheema is an Assistant Professor at the University of Toronto and Head of Medical Oncology/Hematology and Cancer Research at William Osler. She is an internationally known expert in lung cancer and precision cancer care and has conducted numerous clinical trials and published national consensus statements. Her research focuses on lung cancer treatment and immunotherapy and safely and efficiently turning advancements in personalized medicine into day-to-day clinical practice. She founded the William Osler Cancer Immunotherapy Program and has worked closely with her pathology colleagues to develop cancer genomics at William Osler.

Description

Outlining the testing required to deliver modern day targeted therapies to metastatic cancer patients with a focus on lung, colon, and melanoma.

At the end of the session, participants will be able to:
• Facilitate the deliver of molecular results to your local oncologist.
• Discuss the relevant tests needed for treatment of NSCLC, CRC, and MM.

Target audience: Pathologists, Residents, Medical Students, Technicians

CanMEDS Roles: Medical Expert (the integrating role), Communicator, Collaborator, Health Advocate

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Association of Pathologists. You may claim a maximum of 1.5 hour (credits are automatically calculated).

This webinar was co-developed with Pfizer & CAP-ACP and was planned to achieve scientific integrity, objectivity and balance.

This content is restricted to subscribers

Register